The White House continues to push for a "most favored nation" (MFN) drug pricing model to ensure Americans have prices comparable to those in other developed countries[1][2]. Despite a lukewarm reception from Congress, he is trying to step up pressure on lawmakers to pass the bill [original article]. On May 12, 2025, President Trump signed an executive order to impose MFN prices, and on July 31, 2025, he sent letters to pharmaceutical companies demanding lower prices[2][4]. By the end of 2025, 16 manufacturers have entered into voluntary agreements on MFN prices for high-cost drugs that apply to state Medicaid programs and cash-paying consumers[3]. Examples of reductions include Merck's Januvia from $330 to $100, Novartis' Mayzent from $9,987 to $1,137, Ozempic and Wego from around $1,000-$1,350 to $350 per month through TrumpRx[2][4][7]. These agreements also ensure MFN prices for new drugs and the repatriation of foreign earnings to the US[2][6]. In the "Great Healthcare Plan" of January 15, 2026, the White House proposes to codify these agreements into law[3][5][7].